Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03FVI
|
||||
| Former ID |
DIB001733
|
||||
| Drug Name |
97-139
|
||||
| Synonyms |
S-0139; SB-737004; 737004; [4aS-(4abeta,6aalpha,6bbeta,12abeta,14bbeta]-6a-[3-[2-(3-Carboxy-2(E)-propenamido)-5-hydroxyphenyl]-2(E)-propenoyloxymethyl]-2,2,6b,9,9.12a-hexamethyl-10-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a
|
||||
| Indication | Cerebrovascular disorders [ICD10:I60-I69] | Discontinued in Phase 2 | [1] | ||
| Target and Pathway | |||||
| Target(s) | Endothelin-1 receptor | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Renin secretion | |||||
| Pathways in cancer | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Pathway Interaction Database | Endothelins | ||||
| EGFR-dependent Endothelin signaling events | |||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009311) | ||||
| REF 2 | S-0139 (Shionogi). Curr Opin Investig Drugs. 2002 Jul;3(7):1051-6. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.